Extracellular sphingosine-1-phosphate: a novel actor in human glioblastoma stem cell survival

Elena Riccitelli1, Paola Giussani, Clara Di Vito

  • 1Department of Medical Biotechnology and Translational Medicine, University of Milan, LITA-Segrate, Milan, Italy.

Plos One
|July 5, 2013
PubMed

Insights

Glioblastoma stem-like cells (GSCs) produce extracellular sphingosine-1-phosphate (S1P), promoting their survival and resistance to temozolomide (TMZ). Inhibiting S1P biosynthesis sensitizes GSCs to TMZ, highlighting S1P

Area of Science:

  • Neuro-oncology
  • Cancer Stem Cell Biology
  • Molecular Signaling

Background:

  • Glioblastomas are aggressive brain tumors with limited treatment efficacy.
  • Glioblastoma stem-like cells (GSCs) contribute to tumor progression and therapy resistance.
  • Sphingosine-1-phosphate (S1P) is implicated in promoting malignancy and chemoresistance in GSCs.

Purpose of the Study:

  • To investigate the origin and role of S1P in GSCs.
  • To determine if GSCs are a source of extracellular S1P.
  • To elucidate the contribution of extracellular S1P to temozolomide (TMZ) resistance in GSCs.

Main Methods:

  • Glioblastoma stem-like cells (GSCs) were isolated from U87-MG cell line and primary human glioblastoma cultures.
  • Sphingosine metabolism and S1P release were analyzed using pulse labeling experiments.
  • Cellular and extracellular S1P levels were quantified.
  • The effect of S1P modulation on GSC sensitivity to temozolomide (TMZ) was assessed.

Main Results:

  • GSC models exhibited resistance to temozolomide (TMZ) independent of MGMT expression.
  • GSCs rapidly metabolized sphingosine to S1P, with high extracellular S1P levels and an elevated extracellular/intracellular ratio.
  • Extracellular S1P acted as a survival signal for GSCs, and its inhibition sensitized them to TMZ, an effect reversed by exogenous S1P.

Conclusions:

  • Glioblastoma stem-like cells (GSCs) are a significant source of extracellular sphingosine-1-phosphate (S1P).
  • Extracellular S1P functions as an autocrine/paracrine survival signal, contributing to GSC malignancy and temozolomide (TMZ) resistance.
  • Targeting S1P metabolism or signaling represents a potential therapeutic strategy for glioblastoma.

Related Concept Videos